Lisata Therapeutics Shares Rise 11% After Cancer Drug LSTA1 Granted Orphan Drug Status in EU

By Chris Wack Lisata Therapeutics shares were up 11% to $2.34 after the company said the European Medicines Agency Committee for Orphan Medicinal Products...

Related Keywords

,Chris Wack ,European Commission ,Committee For Orphan Medicinal Products ,European Medicines Agency Committee ,Orphan Medicinal Products ,Orphan Medicinal ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Cancer Drugs ,Scientific Research Services ,Healthcare Life Sciences ,Business Consumer Services ,Specialized Drugs Medications ,Medical Research Services ,Healthcare Support Services ,Diagnostic Medical Research Services ,Stem Cell Research ,Financial Performance ,Share Price Movement Disruptions ,Corporate Industrial News ,Cancer ,Political General News ,Health ,Medical Conditions ,Equity Markets ,Commodity Financial Market News ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Lisata Therapeutics ,Tlsta ,Share Price Movement ,Disruptions ,Corporate ,Industrial News ,Political ,General News ,Commodity ,Financial Market News ,Healthcare ,Life Sciences ,Business ,Consumer Services ,Specialized Drugs ,Medications ,Diagnostic ,